STOCK TITAN

AVEO Pharmaceuticals Inc - AVEO STOCK NEWS

Welcome to our dedicated news page for AVEO Pharmaceuticals (Ticker: AVEO), a resource for investors and traders seeking the latest updates and insights on AVEO Pharmaceuticals.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect AVEO Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of AVEO Pharmaceuticals's position in the market.

Rhea-AI Summary
AVEO Oncology appoints Dr. Edgar E. Braendle as Chief Medical Officer and forms Scientific Advisory Committee with renowned experts in oncology research.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
management
-
Rhea-AI Summary
AVEO Oncology, an LG Chem company, announced the publication of a post-hoc analysis of long-term progression-free survival, overall survival, and safety data from the Phase 3 TIVO-3 trial evaluating FOTIVDA in patients with relapsed or refractory advanced renal cell carcinoma. The analysis showed a consistent safety profile and long-term survival benefit in patients, indicating a durable clinical benefit and safety across age groups regardless of prior treatment. TIVO-3 compared the efficacy and safety of FOTIVDA and sorafenib in patients with advanced RCC, with FOTIVDA demonstrating higher long-term progression-free survival rates and overall survival benefit compared to sorafenib. The study showed lower treatment-related adverse events and dose modification rates with FOTIVDA, highlighting its potential as a safe and effective therapy for patients with refractory RCC.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
clinical trial
-
Rhea-AI Summary
AVEO Oncology, an LG Chem company, has announced the enrollment of the first patient in the FIERCE-HN trial, a phase 3 clinical trial evaluating ficlatuzumab in combination with ERBITUX for the treatment of HPV-negative recurrent or metastatic head and neck squamous cell carcinoma. The trial follows FDA Fast Track Designation and aims to improve survival outcomes in an underserved patient population.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
clinical trial
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
acquisition
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
acquisition
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
earnings
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
acquisition
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
AVEO Pharmaceuticals Inc

Nasdaq:AVEO

AVEO Rankings

AVEO Stock Data

521.45M
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Boston

About AVEO

AVEO Pharmaceuticals Inc. is an oncology-focused biopharmaceutical company committed to delivering medicines that provide a better life for cancer patients. AVEO's strategy is to focus its resources toward the development and commercialization of its product candidates in North America, while leveraging partnerships to support development and commercialization in other geographies. AVEO's lead candidate, FOTIVDA® (tivozanib), received U.S. Food and Drug Administration (FDA) approval on March 10, 2021 for the treatment of adult patients with relapsed or refractory renal cell carcinoma (RCC) following two or more prior systemic therapies. FOTIVDA® was approved in August 2017 in the European Union and other countries in the EUSA territory for the treatment of adult patients with advanced RCC. AVEO has previously reported promising early clinical data on ficlatuzumab (anti-HGF IgG1 mAb) in head and neck cancer, pancreatic cancer and acute myeloid leukemia and is conducting a randomized Phase 2 confirmatory clinical trial of ficlatuzumab for the potential treatment of head and neck cancer. AVEO's pipeline of product candidates also includes AV-380 (anti-GDF15 IgG1 mAb). AVEO has previously reported the acceptance of its investigational new drug application in the U.S. for AV-380 and its initiation of a Phase 1 clinical trial for the potential treatment of cancer cachexia. AVEO's earlier-stage pipeline includes monoclonal antibodies in oncology development, including AV-203 (anti-ErbB3 mAb) and AV-353 (anti-Notch 3 mAb). AVEO is committed to creating an environment of diversity and inclusion.